Compare TYRA & CEPU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TYRA | CEPU |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2021 | 2017 |
| Metric | TYRA | CEPU |
|---|---|---|
| Price | $26.04 | $13.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $47.50 | $17.50 |
| AVG Volume (30 Days) | ★ 630.1K | 186.0K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $7.43 |
| 52 Week High | $40.65 | $18.50 |
| Indicator | TYRA | CEPU |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 39.85 |
| Support Level | $24.77 | N/A |
| Resistance Level | $32.82 | $15.76 |
| Average True Range (ATR) | 1.75 | 0.57 |
| MACD | -0.67 | -0.12 |
| Stochastic Oscillator | 7.53 | 6.72 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity. The company derives maximum revenue from Electric Power Generation from conventional sources segment.